MSLN and ovarian carcinoma: initiated a Phase I clinical investigation to evaluate the safety and applicability of these CAR-Ts in individuals with ovarian cancer (proficient in the expression of glypican 3 or mesothelin), as well as other advanced solid tumors (NCT03198546) (151).